EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort

Tissana Prasartseree, Pittaya Dankulchai, Wiwatchai Sittiwong, Phattarapol Laolugsanalerd, Sirapob Seksunwiriya, Soponvit Wattanakul, Tewpaithong Rodwong, Peerakarn Charoenwong, Wasawat Jirasuviboon, Nonpawit Suriyanusorn, Akrapol Suppasedtanon, Chayanis Kositamongkol und 2 weitere

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2026.08.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brachytherapy, 2026. Verfasst von Tissana Prasartseree und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Siriraj Brachyt…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Radiation Dose Hypofractionation, Uterine Cervical Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate 2-year late gastrointestinal (GI) toxicity, oncologic outcomes, and cost-effectiveness of hypofractionated concurrent chemoradiation with 44 Gy in 20 fractions (44 Gy/20F; HYPO) versus conventional fractionation (45 Gy/25F; CVRT + EMB) for locally advanced cervical cancer (LACC). METHODS: The primary analysis was the randomized HYPOCx-iRex comparison (HYPO n = 21 vs. CVRT n = 19). A pre-planned pooled analysis additionally incorporated a concurrent, nonrandomized single-institute EMBRACE-II cohort (EMB n = 28; total n = 68). Late GI toxicity was graded by CTCAEv5.0. Dose-toxicity analysis used Cox and Probit regression to identify the effective dose associated with 10% toxicity probability (ED10). The indirect ratio of excess dose volume at 60 Gy EQD2 (iRex60) was evaluated as a brachytherapy (BT) conformity index. Locoregional control (LRC) and overall survival (OS) were estimated by Kaplan-Meier. Incremental cost-effectiveness ratios (ICERs) were calculated from provider and societal perspectives. RESULTS: Median overall treatment time was 39 versus 46 days in HYPO versus CVRT+EMB (p < 0.001). Late GI toxicity was numerically higher in HYPO (2-year Gr ≥2: 23.8% vs. 10.8%, pLR = 0.168; Gr ≥3: 19.1% vs. 5.3%, pLR = 0.066); iRex60 was identified as an independent predictor in multivariable regression (ED10 = 1.6 and 1.85 for Gr ≥2/Gr ≥3; proposed cut-off iRex60

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyRadiation Dose HypofractionationUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedBrachytherapyCohort StudiesCost-Benefit AnalysisCost-Effectiveness AnalysisDose Fractionation, RadiationTreatment Outcome

Stichwörter der Autor:innen

Altered fractionationBrachytherapyCervixConformity indexHypofractionationOverall treatment time

Autor:innen und Institutionen

  • Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Siriraj Brachytherapy Center (SiBTC), Siriraj Center of Excellence (SiCOE), Faculty o…
  • Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj…
  • Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Radiation Medicine, University of Wisconsin-Madison, Madison, WI.

Zitieren

APA

Prasartseree, T., Dankulchai, P., Sittiwong, W., Laolugsanalerd, P., Seksunwiriya, S., Wattanakul, S., Rodwong, T., Charoenwong, P., Jirasuviboon, W., Suriyanusorn, N., Suppasedtanon, A., Kositamongkol, C., Phisalprapa, P., & Klopp, A. H. (2026). Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort. Brachytherapy. https://doi.org/10.1016/j.brachy.2026.08.004

Vancouver

Prasartseree T, Dankulchai P, Sittiwong W, Laolugsanalerd P, Seksunwiriya S, Wattanakul S, et al. Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort. Brachytherapy. 2026. doi:10.1016/j.brachy.2026.08.004

BibTeX
@article{Prasartseree2026,
  author = {Prasartseree, Tissana and Dankulchai, Pittaya and Sittiwong, Wiwatchai and Laolugsanalerd, Phattarapol and Seksunwiriya, Sirapob and Wattanakul, Soponvit and Rodwong, Tewpaithong and Charoenwong, Peerakarn and Jirasuviboon, Wasawat and Suriyanusorn, Nonpawit and Suppasedtanon, Akrapol and Kositamongkol, Chayanis and Phisalprapa, Pochamana and Klopp, Ann H},
  title = {Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2026.08.004}
}
Kostenlos starten →